- IN₹179.00bn
- IN₹169.32bn
- IN₹27.07bn
- 92
- 31
- 98
- 90
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.69 | ||
| PEG Ratio (f) | 0.87 | ||
| EPS Growth (f) | 15.55% | ||
| Dividend Yield (f) | 1.1% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.38 | ||
| Price to Tang. Book | 3.51 | ||
| Price to Free Cashflow | 32.62 | ||
| Price to Sales | 4.68 | ||
| EV to EBITDA | 10.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 26.43% | ||
| Return on Equity | 25.91% | ||
| Operating Margin | 37.11% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 20,945 | 19,150 | 20,521 | 19,448 | 27,071 | 39,202 | 45,121.38 | 4.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -11.29 | -28.48 | -6.99 | -67.79 | +423.4 | +92.35 | +15.55 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
Directors
- V. Nannapaneni CHM (68)
- Rajeev Nannapaneni CEO (37)
- S. V. V. N. Appa Rao CFO
- Linga Rao CEX
- P. S. R. K. Prasad EVP
- M. Adinarayana CCO
- Sridhar Sankararaman DRC (37)
- Leela Digumarti IND
- M. U. R. Naidu IND
- D. Prasad IND
- T. Rao IND
- G. Murthy NID (77)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 19th, 1981
- Public Since
- January 23rd, 1995
- No. of Shareholders
- 153,678
- No. of Employees
- 3,979
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 179,109,870
- Address
- Natco House, Road No 2, Banjara Hills, HYDERABAD, 500034
- Web
- http://www.natcopharma.co.in/
- Phone
- +91 4023547532
- Contact
- Chekuri Ramesh
- Auditors
- B S R & Associates LLP
Latest News for NATCOPHARM
Upcoming Events for NATCOPHARM
Q4 2024 Natco Pharma Ltd Earnings Release
Q1 2025 Natco Pharma Ltd Earnings Release
Natco Pharma Ltd Annual Shareholders Meeting
Similar to NATCOPHARM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:15 UTC, shares in Natco Pharma are trading at IN₹999.40. This share price information is delayed by 15 minutes.
Shares in Natco Pharma last closed at IN₹999.40 and the price had moved by +80.43% over the past 365 days. In terms of relative price strength the Natco Pharma share price has outperformed the S&P BSE 100 Index by +39.94% over the past year.
The overall consensus recommendation for Natco Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Natco Pharma dividend yield is 0.95% based on the trailing twelve month period.
Last year, Natco Pharma paid a total dividend of IN₹9.50, and it currently has a trailing dividend yield of 0.95%. We do not have any data on when Natco Pharma is to next pay dividends.
We do not have data on when Natco Pharma is to next pay dividends. The historic dividend yield on Natco Pharma shares is currently 0.95%.
To buy shares in Natco Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹999.40, shares in Natco Pharma had a market capitalisation of IN₹179.00bn.
Here are the trading details for Natco Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: NATCOPHARM
Based on an overall assessment of its quality, value and momentum Natco Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Natco Pharma is IN₹862.85. That is 13.66% below the last closing price of IN₹999.40.
Analysts covering Natco Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹74.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Natco Pharma. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +3.89%.
As of the last closing price of IN₹999.40, shares in Natco Pharma were trading +17.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Natco Pharma PE ratio based on its reported earnings over the past 12 months is 11.69. The shares last closed at IN₹999.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Natco Pharma's management team is headed by:
- V. Nannapaneni - CHM
- Rajeev Nannapaneni - CEO
- S. V. V. N. Appa Rao - CFO
- Linga Rao - CEX
- P. S. R. K. Prasad - EVP
- M. Adinarayana - CCO
- Sridhar Sankararaman - DRC
- Leela Digumarti - IND
- M. U. R. Naidu - IND
- D. Prasad - IND
- T. Rao - IND
- G. Murthy - NID